GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Cyclically Adjusted PB Ratio

Coherus BioSciences (FRA:8C5) Cyclically Adjusted PB Ratio : 5.43 (As of Jun. 10, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Cyclically Adjusted PB Ratio?

As of today (2024-06-10), Coherus BioSciences's current share price is €1.575. Coherus BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €0.29. Coherus BioSciences's Cyclically Adjusted PB Ratio for today is 5.43.

The historical rank and industry rank for Coherus BioSciences's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:8C5' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 5.26   Med: 15.86   Max: 38.7
Current: 5.26

During the past years, Coherus BioSciences's highest Cyclically Adjusted PB Ratio was 38.70. The lowest was 5.26. And the median was 15.86.

FRA:8C5's Cyclically Adjusted PB Ratio is ranked worse than
80.33% of 661 companies
in the Biotechnology industry
Industry Median: 1.67 vs FRA:8C5: 5.26

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Coherus BioSciences's adjusted book value per share data for the three months ended in Mar. 2024 was €-0.663. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.29 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Coherus BioSciences Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Coherus BioSciences's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Cyclically Adjusted PB Ratio Chart

Coherus BioSciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 29.72 9.74

Coherus BioSciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.23 17.71 18.19 9.74 7.44

Competitive Comparison of Coherus BioSciences's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Coherus BioSciences's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coherus BioSciences's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus BioSciences's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Coherus BioSciences's Cyclically Adjusted PB Ratio falls into.



Coherus BioSciences Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Coherus BioSciences's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.575/0.29
=5.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coherus BioSciences's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Coherus BioSciences's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.663/131.7762*131.7762
=-0.663

Current CPI (Mar. 2024) = 131.7762.

Coherus BioSciences Quarterly Data

Book Value per Share CPI Adj_Book
201406 -3.365 100.560 -4.410
201409 -3.676 100.428 -4.823
201412 1.629 99.070 2.167
201503 1.046 99.621 1.384
201506 2.255 100.684 2.951
201509 0.932 100.392 1.223
201512 -0.146 99.792 -0.193
201603 -1.514 100.470 -1.986
201606 -1.255 101.688 -1.626
201609 0.671 101.861 0.868
201612 0.425 101.863 0.550
201703 1.425 102.862 1.826
201706 0.557 103.349 0.710
201709 0.814 104.136 1.030
201712 0.449 104.011 0.569
201803 -0.024 105.290 -0.030
201806 0.798 106.317 0.989
201809 0.156 106.507 0.193
201812 -0.497 105.998 -0.618
201903 -0.492 107.251 -0.605
201906 -0.051 108.070 -0.062
201909 0.726 108.329 0.883
201912 1.346 108.420 1.636
202003 2.008 108.902 2.430
202006 2.656 108.767 3.218
202009 3.014 109.815 3.617
202012 3.185 109.897 3.819
202103 1.467 111.754 1.730
202106 1.696 114.631 1.950
202109 1.451 115.734 1.652
202112 1.124 117.630 1.259
202203 0.147 121.301 0.160
202206 -0.275 125.017 -0.290
202209 -1.261 125.227 -1.327
202212 -1.645 125.222 -1.731
202303 -2.280 127.348 -2.359
202306 -1.708 128.729 -1.748
202309 -1.147 129.860 -1.164
202312 -1.581 129.419 -1.610
202403 -0.663 131.776 -0.663

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Coherus BioSciences  (FRA:8C5) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Coherus BioSciences Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Coherus BioSciences's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Coherus BioSciences (FRA:8C5) Business Description

Traded in Other Exchanges
Address
333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines